Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,304 INR | +3.90% |
|
+7.95% | +20.25% |
Jun. 27 | Aurobindo Pharma Arm's Injectable Facility Gets 'Voluntary Action Indicated' Classification from US FDA | MT |
Jun. 24 | INDIA STOCKS-Financials weigh on Indian shares; small-, mid-caps fall | RE |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- The company is in a robust financial situation considering its net cash and margin position.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- With a 2024 P/E ratio at 24.44 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+20.25% | 9.15B | B | ||
+56.89% | 823B | C+ | ||
+39.52% | 627B | B | ||
-6.55% | 353B | C+ | ||
+15.99% | 320B | B- | ||
+7.92% | 295B | C+ | ||
+13.74% | 239B | B+ | ||
+13.83% | 220B | B- | ||
-0.49% | 219B | A+ | ||
+7.94% | 167B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- AUROPHARMA Stock
- Ratings Aurobindo Pharma